Review anchor
A-type voltage-gated potassium channel KCND3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
A-type voltage-gated potassium channel KCND3
CHEMBL1964
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats A-type voltage-gated potassium channel KCND3 as ChEMBL target CHEMBL1964, mapped to UniProt Q9UK17. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1964
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9UK17
A-type voltage-gated potassium channel KCND3
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why A-type voltage-gated potassium channel KCND3 matters
A-type voltage-gated potassium channel KCND3 is reviewed as A-type voltage-gated potassium channel KCND3 (UniProt Q9UK17); A-type voltage-gated potassium channel KCND3 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 10 approved drugs, 93 compounds, and 85 assays, with lead potency reaching pChEMBL 5.8.
Protein context
A-type voltage-gated potassium channel KCND3
A-type voltage-gated potassium channel KCND3 Sequence length is 655 aa.
Review this target as A-type voltage-gated potassium channel KCND3, mapped to UniProt Q9UK17. Sequence length is 655 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9UK17
Protein
Disease context
atrial fibrillation
A-type voltage-gated potassium channel KCND3 shows approved-linked disease relevance led by atrial fibrillation. 1 more disease program remain visible in the same review block. 1 linked drug keep the rationale reviewable. 1 additional disease programs remain visible in the same card. Linked drugs include VERNAKALANT HYDROCHLORIDE.
Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include VERNAKALANT HYDROCHLORIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 10 approved drugs, 93 compounds, and 85 assays for this target. The dominant activity type is IC50. CHEMBL44297 is the current potency anchor at pChEMBL 5.8.
Use CHEMBL44297 as the tractability anchor when discussing potency (pChEMBL 5.8).
Activity source · ChEMBL 36 via Core Engine
10 approved
pChEMBL 5.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why A-type voltage-gated potassium channel KCND3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9UK17, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why atrial fibrillation is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
93
Total Compounds
85
Total Assays
10
Approved Drugs
IC50: 49.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL44297
|
5.8 | IC50 | — |
|
|
No preferred name
CHEMBL4065169
|
5.6 | IC50 | — |
|
|
No preferred name
CHEMBL569185
|
5.4 | IC50 | — |
|
|
No preferred name
CHEMBL2042163
|
5.2 | IC50 | — |
|
|
No preferred name
CHEMBL4104525
|
5.1 | IC50 | — |
Source Header